Skip to content

Author

Sören Möller

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Interferon-α vs hydroxyurea in patients with myeloproliferative neoplasms (DALIAH): a multicentre, randomised, open-label, phase 3 trial in Denmark

Summary Background Hydroxyurea (HU) is the most commonly used cytoreductive treatment for patients with myeloproliferative neoplasms (MPN), but emerging data on pegylated interferon-alpha2 (pegIFNα) are encouraging. Optimal first-line treatment remains unclear. Methods DALIAH was a randomised, open-label, parallel-grou...

T. Knudsen, D. Hansen, L. F. Ocias et al. · 0 citations
Open access Oct 2026

Patient characteristics and quality of life in relation to place of death in lung cancer patients treated with immunotherapy

Abstract Objectives Studies show that cancer patients consider place of death (POD) an important factor influencing quality of life (QoL) at the end of life. The objectives of this study were to identify characteristics of real-world non-small cell lung cancer (NSCLC) patients based on POD and investigate how changes i...

Amalie Rasmussen, L. H. Land, Sören Möller et al. · 0 citations
Review Open access Oct 2026

Frailty and quality of life in a real-world multiple myeloma population.

The results based on a real-world population show that QoL findings from clinical trial populations cannot directly be applied to frail patients.

K. Rydahl, Sören Möller, T. Horsbøl et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.